New study aims to prevent dangerous acid buildup in type 1 diabetes

NCT ID NCT07225465

First seen Nov 06, 2025 · Last updated May 13, 2026 · Updated 20 times

Summary

This study tests whether using a lower ketone alarm (1.0 vs 1.5 mmol/L) can safely reduce the risk of diabetic ketoacidosis (DKA) in people with type 1 diabetes taking dapagliflozin, a drug usually used for type 2 diabetes. About 115 adults will wear a continuous ketone monitor and take the drug for 12 weeks. The goal is to find the best way to catch rising ketones early and prevent DKA.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Austin Health

    Heidelberg, Victoria, 3084, Australia

    Contact Phone: •••-•••-••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Baker Heart and Diabetes Institute

    Melbourne, Victoria, 3004, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • St Vincent's Hospital Melbourne

    Fitzroy, Victoria, 3065, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Royal Melbourne Hospital

    Parkville, Victoria, 3050, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.